Nicox SA logo

Nicox SA - Share from reverse s

LTS:0RCQ (France)   Share from reverse split
€ 0.40 (0%) May 13
At Loss
P/B:
0.88
Market Cap:
€ 18.75M ($ 20.23M)
Enterprise V:
€ 32.64M ($ 35.22M)
Volume:
-
Avg Vol (2M):
82.00
Also Trade In:

Business Description

Description
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
Name Current Vs Industry Vs History
Cash-To-Debt 0.45
Equity-to-Asset 0.4
Debt-to-Equity 1.18
Debt-to-EBITDA -1.56
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -14.59
Distress
Grey
Safe
Beneish M-Score -6.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 44.44
9-Day RSI 47.06
14-Day RSI 48.14
6-1 Month Momentum % -3.8
12-1 Month Momentum % -31.93

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.97
Quick Ratio 8.97
Cash Ratio 1.97
Days Sales Outstanding 3767.41
Days Payable 88.62

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.7
Shareholder Yield % 2.4

Financials (Next Earnings Date:2024-05-31 Est.)

LTS:0RCQ's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Nicox SA Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.257
EPS (TTM) (€) -0.415
Beta 0.05
Volatility % 34.74
14-Day RSI 48.14
14-Day ATR (€) 0.39648
20-Day SMA (€) 0.571299
12-1 Month Momentum % -31.93
52-Week Range (€) 0.3195 - 3.74047
Shares Outstanding (Mil) 49.99

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Nicox SA Filings

Filing Date Document Date Form
No Filing Data

Nicox SA Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Nicox SA Frequently Asked Questions

What is Nicox SA(LTS:0RCQ)'s stock price today?
The current price of LTS:0RCQ is €0.40. The 52 week high of LTS:0RCQ is €3.74 and 52 week low is €0.32.
When is next earnings date of Nicox SA(LTS:0RCQ)?
The next earnings date of Nicox SA(LTS:0RCQ) is 2024-05-31 Est..
Does Nicox SA(LTS:0RCQ) pay dividends? If so, how much?
Nicox SA(LTS:0RCQ) does not pay dividend.

Press Release

Subject Date
No Press Release